Whitehawk, OzAurum, Argent Biopharma & Galan

Whitehawk Ltd (ASX: WHK)

increase of 300% (0.8 ° C – 3.2 ° C)

Bulls N ‘Bears Asx Runner of the week is the Whitehawk Limited computer security company, which saw the price of the actions to go to the stars at a maximum of 3.2 cents on Wednesday more than 300 % from an end of 0.8 ° C last week.

The price of the company’s shares became ballistic after sautéing an important place as the main computer partner in a huge government contract of the United States (a $ 1474 million), with the leaders of the Knexus Research, Babel Street and Dun & Bradstreet sector.

Whitehawk states that it will be the only partner of computer solution to provide tools fueled by artificial intelligence for the management of IT risks in federal supply chains during the 10-year agreement, which could lead to substantial recurring revenues for the micro-capital company as the orders of activities are continuously issued.

The contract is supported by an executive order of the White House of 2025 and will simplify the contracts of the government, potentially opening even more opportunities for Whitehawk.

The size of the contract, combined with the fundamental role of Whitehawk, probably triggered investors to stack the title after his announcement on Tuesday morning.

Whitehawk has experienced a huge volume of $ 6 million during the week with its market capitalization which has finally satisfied himself of just over $ 12 million on Friday.

Whitehawk is offering its tools based on artificial intelligence for the management of the computer risk of the supply chain for the United States government in the midst of a growing global emphasis on IT security and technological innovation. The company could have the internal track for many other contracts that have been exploited as a provider of US governments premium.

Ozourum Resources Ltd (ASX: OZM)

Up 94% (6,7c – 13c)

Ozaurum Resources took second place on the ASX Runner of Week list this week after the price of the Taken Gold Junior shares increased 94 % to end up at 13 ° C. Over $ 7 million for the company’s shares.

The company has revealed the results of the discovery of the inverse circulation from its Mulgabbie North Gold project in Western Australia on the same day when the gold price torn from a new maximum of all time. The discovery of its prospect of crossed fault presented impressive thick blows, of which 48 meters at 1.66 grams per ton (g/t) in gold with a surface and 12 m of classification of about 4.26 g/t 18 m.

Ozaurum will not waste time to start a follow-up perforation program, including diamond drill tests, as soon as next week. The short -term attention of the company is to expand its 260,000 ounce gold resources through its project.

The perforation program of this week successfully confirmed the presence of high -grade gold mineralization on a substantial strike of 400 million.

Ozaurum seems to have fooled a high -level discovery and hosted in sandstone, with gold mineralization and a large vein of quartz next to the mineralization of pyrite and arsenopirite. Large areas of sulphides have also been intersecting, indicating the potential for a significant golden equipment, says Ozaurum.

The sandstones are a fragile guest rock and are the distinctive sign of the large gold deposits that are extracted in the 4 m Carosue Dam Basin of extremely profitable ounces, just 2 km from Mulgabbie North.

The company believes that its new transversal failure objective is on the cutting of relief at about 2 km south of the current mineral resource of the North Mulgabbie of 260,000 ounces along the same cut.

The tests remain to be elaborated for a further seven perforated inverse circulation holes for 745 m, leaving a lot of meat on the bone for the shareholders who move at the tip for gold essays of any kind, in an equity market otherwise without love.

Argent Biopharma Ltd (Asx: RGT)

UP 69% (16C – 27C)

The finish of the final podium of the runners goes to the Argent Biopharma Limited Biotechnology developer after the company revealed that its therapy based on top cannabinoids had been approved for the prescription in Germany as part of a special access scheme.

Argent’s actions price rises on Thursday touching on 27 ° C at a certain point, which increased by 69 % compared to the closure of last week of 16 ° C per action. The price has increased by only $ 110,000 of actions exchanged in a strictly kept register, in which the card rarely changes from hand.

Argent flagship cannon therapy has a low CBD liquid formulation with a low Thc content orally delivered to patients suffering from a form of drug -resistant epilepsy.

The CBD in cannabis is increasingly considered for the treatment of a series of medical conditions, while TBA is the molecule responsible for its hallucinogenic effects.

Argent states that about 816,000 people in Germany is diagnosed every year with epilepsy and a substantial part of those patients will have a resistant form to disease drugs. He believes that Cannepil will offer a treatment that changes life for patients who have no current attractive alternative.

Rooming his presence in Germany – a key pharmaceutical hub – Argent has penetrated a substantial barrier at the entrance to the high priority of the European market.

With an increasing number of cannabinoid -based medicines that obtain global acceptance, the turning point marks the first Argent cannabis therapy to be recognized for its central nervous system applications. The company seems sure that this company will not be its last.

Galan Lithium Ltd (ASX: GLN)

UP 45% (11c – 16C)

The Lithio Galan Lithium developer obtains a remarkable mention on the list of ASX runners this week, after having swirl the trend in a disastrous week for lithium thanks to its low -cost Argentine lithium project in the world -level lithium triangle.

The company has ricled a 150 million dollar cash (an offer of $ 240 million) by Zhejiang Huayou Cobalt Cobalt co and Renault of the Renault group of USA to acquire his Hombre Muerto West (HMW) and the lithium candle room projects in Argentina, labeling the “opportunistic” and “underestimated” proposal.

The offer The refusal was hidden within a secondary commercial notice of Thursday morning, which saw the price of the shares of the unchanged company open.

The market quickly cooked, with the price of Galan shares that charged almost 50 % to a maximum of 16 ° C per action by a market capitalization of $ 92 million per week before a maximum of $ 134 million intraday.

This level was well short of the acquisition in cash proposal of $ 240 million.

The wave challenged a wider market recession.

The proposal not requested, conditional and not binding from the Zhejiang Huayou battery material giant and the producer of EV Renault has been the second offer not required by Galan for less than a year.

Last August, Galan also received an indicative proposal that is not requested, confidential, conditional, not binding from the Energy exploration technologies to acquire Argentine activities for $ 100 million in cash and scripts, which the company has fought quickly.

Galan believes that the completion of the acquisition and financing agreements for the first phase of HMW will occur shortly, leading to a more certain and higher acquisition result than the offer of $ 240 million which was “only” 2.6 times the previous market capitalization of the company.

Galan’s HMW and Candela projects have a resource equivalent to the lithium of carbonate (LCE) of 9.5 m of tonne at 841 milligrams of high degree for litigation (MG/L) and the company is more than half of the phase one production.

The project is located only 100 km south of the RiCon project in Rio Tinto, also within the important Argentine lithium triangle. The LCE non Jorc resource of Rincon 5.8 meters was acquired by the mining giant in 2022 for just over $ 1 billion in a more lively lithium prices. It is important to underline that Galan’s Hombre Muerto Salar presents the lithium degrees doubled to that of the Rincon Project, which reaches about 420 mg/l.

Galan’s decision to defeat the buyers for its low -cost lithium development seems disconcerting, but the direction seems willing to guarantee the right price for its vast project. Perhaps in a moment of stronger lithium prices or once you “soon” ensures a partner of acquisition and funding.

Is your company listed in Asx doing something interesting? Contact: matebirney@bullsnbears.com.au